Jonathan D. Campbell

Jonathan D. Campbell publication distribution in Economics and Finance in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Economics and Finance in 2026. The highlighted bar marks where Jonathan D. Campbell sits on this spectrum.

Jonathan D. Campbell D-index placement in Economics and Finance in 2026

The chart shows the D-index (discipline H-index) distribution of Economics and Finance scientists ranked by Research.com in 2026. The highlighted bar marks where Jonathan D. Campbell sits on this spectrum.

Best Publications

• Multiple sclerosis prevalence in the United States commercially insured population

  Piyameth Dilokthornsakul;Robert J. Valuck;Kavita V. Nair;John R. Corboy

  304
  Citations

• The costs of treating breast cancer in the US: a synthesis of published evidence.

  Jonathan D. Campbell;Scott D. Ramsey;Scott D. Ramsey

  164
  Citations

• Community Health Worker Home Visits for Medicaid-Enrolled Children With Asthma: Effects on Asthma Outcomes and Costs.

  Jonathan D. Campbell;Marissa Brooks;Patrick Hosokawa;June Robinson

  158
  Citations

• Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates

  Jonathan D. Campbell;Vahram Ghushchyan;R. Brett McQueen;Sharon Cahoon-Metzger

  150
  Citations

• Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis.

  William V. Padula;Shiona Heru;Jonathan D. Campbell

  145
  Citations

• Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries.

  Bertalan Németh;Anett Molnár;Sándor Bozóki;Sándor Bozóki;Kalman Wijaya

  134
  Citations

• Asthma outcomes: Healthcare utilization and costs

  Lara J. Akinbami;Sean D. Sullivan;Jonathan D. Campbell;Robert W. Grundmeier

  110
  Citations

• The promise of Immuno-oncology: implications for defining the value of cancer treatment.

  Howard L. Kaufman;Michael B. Atkins;Prasun Subedi;James Wu

  108
  Citations

• Validation of an algorithm for identifying MS cases in administrative health claims datasets

  William J. Culpepper;Ruth Ann Marrie;Annette Langer-Gould;Mitchell T. Wallin

  100
  Citations

• Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke

  Michelle H. Leppert;Jonathan D. Campbell;Jennifer R. Simpson;James F. Burke

  99
  Citations

• The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.

  J. D. Campbell;D. E. Spackman;S. D. Sullivan

  98
  Citations

• Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis

  Melanie D. Whittington;R. Brett McQueen;Daniel A. Ollendorf;Jeffrey A. Tice

  95
  Citations

• Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations

  R Brett McQueen;Danielle N Sheehan;Melanie D Whittington;Job F M van Boven

  94
  Citations

• Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?

  Anne Mason;Michael Drummond;Scott Ramsey;Jonathan Campbell

  89
  Citations

• Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes

  R Brett McQueen;Samuel L Ellis;Jonathan D Campbell;Kavita V Nair

  83
  Citations

• Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

  Melanie D. Whittington;R. Brett McQueen;Daniel A. Ollendorf;Varun M. Kumar

  81
  Citations

• Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.

  Melanie D Whittington;R Brett McQueen;Daniel A Ollendorf;Varun M Kumar

  77
  Citations

• Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder.

  Jonathan H. Watanabe;Jonathan D. Campbell;Arliene Ravelo;Michael B. Chancellor

  70
  Citations

• Adherence to Statins in Primary Prevention: Yearly Adherence Changes and Outcomes

  Julia F. Slejko;P. Michael Ho;Heather D. Anderson;Kavita V. Nair

  68
  Citations

• Measuring the cost of poor asthma control and exacerbations

  Patrick W Sullivan;Vahram H Ghushchyan;Jonathan D Campbell

  51
  Citations